Genflow Biosciences PLC (GENF)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.80p

Buy

0.90p

arrow-down-0.025p (-2.86%)

Prices updated at 30 May 2025, 16:28 BST

Prices minimum 15 mins delay

Prices in GBX

FTSE All-Share

0.58%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Ms. Tamara L. Joseph

CEO

Dr. Eric J. Leire

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

-

Head office

6 Heddon Street

London

United Kingdom

W1B 4BT

+44 2081425409

info@genflowbio.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. Tamara L. Joseph Non-Executive Director, Chairman	-
Dr. Yassine Bendiabdallah Non-Executive Director	-
Dr. Peter King-Lewis Non-Executive Director	-
Dr. Guy-Charles Fanneau de la Horie Non-Executive Director	-
Dr. Eric J. Leire Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Miton UK Microcap	16,000,000
Miton Asset Management Limited	4,611,262
Premier Miton UK Smaller Companies	4,611,262

Director dealings

Date chevron-l-regular chevron-r-regular	Action
15 May 2025	Purchase
27 Mar 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.